Targeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained response

Snyder, Benjamin M.Lion, Alex H.Helvie, Amy E.Marshall, Mark S.Ferguson, Michael J.2023-10-182023-10-182023-01-03Snyder BM, Lion AH, Helvie AE, Marshall MS, Ferguson MJ. Targeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained response. Clin Case Rep. 2023;11(1):e6779. Published 2023 Jan 3. doi:10.1002/ccr3.6779https://hdl.handle.net/1805/36432Here we present a case of metastatic PNET which arose from an immature teratoma that was refractory to standard Ewing sarcoma chemotherapy. This PNET was determined to have elevated levels of ALK protein via IHC. The patient was treated with crizotinib on a palliative basis with a sustained response.en-USAttribution 4.0 InternationalEwing sarcomaPNETCrizotinibPrecision oncologyTargeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained responseArticle